Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Acute Kidney Injury Aki Epidemiology Forecast

DelveInsight’s ‘Acute Kidney Injury (AKI) - Epidemiology Forecast– 2030’ report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology as well as the AKI market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Acute Kidney Injury Disease Understanding

Acute Kidney Injury Overview

Acute Kidney Injury (AKI), also known as acute renal failure (ARF) is a condition characterized by azotemia that progresses over several hours or days, with or without oliguria. AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes. According to the Kidney Disease: Improving Global Outcomes (KDIGO), AKI is defined as any of the following (not graded):


  • Increase in serum creatinine (SCr) by = 0.3 mg/dl (= 26.5 µmol/l) within 48 hours.
  • Increase in SCr to = 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days.
  • Urine volume < 0.5 ml/kg/hour for 6 hours.


In 1802, William Heberden termed the first description of AFR, Ischuria renalis. At the beginning of the twentieth century, ARF termed as Acute Bright’s disease was described in William Osler’s Textbook for Medicine (1909), to be “as a consequence of toxic agents, pregnancy, burns, trauma or operations on the kidneys”. During the First World War, the syndrome was named war nephritis and was reported in several publications. The syndrome was forgotten until the Second World War when Bywaters and Beall published their classical paper on crush syndrome. Acute tubular necrosis (ATN) was the term that was used to describe this clinical entity, because of histological evidence for patchy necrosis of renal tubules at autopsy. For many years in clinical practice, the terms ATN and ARF were used interchangeably. However, it is Homer W. Smith who is credited with the introduction of the term AKI, in a chapter on AKI related to traumatic injuries in his 1951 textbook. The kidney-structure and function in health and disease. Until recently, a precise biochemical definition for ARF was missing. As a consequence, there was no consensus on the diagnostic criteria, resulting in multiple different definitions. A 2002 survey revealed at least 35 definitions in the scientific literature.

Acute Kidney Injury Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI, and Age-specific Incident Population of AKI in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.


Key Findings

This section provides glimpse of the AKI epidemiology in the 7MM.

  • In 2020, the incident population of AKI in the 7MM was 10,907,615. The mortality adjusted incident population of AKI in hospitalized patients in the seven major market, was estimated to be 6,544,569 in 2020.
  • The United States encompasses the highest incident population of AKI in hospitalized patients, compared to EU5 and Japan. In the United States, mortality adjusted incident population of AKI in hospitalized patients accounted for 2,231,147 in 2020.
  • In 2020, in the United States, there were 1,584,114, 401,606, and 245,426 cases of stage I, stage II, and stage III AKI respectively.
  • In the US, the age group of 60–84 accounted for the highest cases in 2020, followed by 85+ years. In contrast, the least cases were found in the age group of 18–59. In 2020, there were 312,361, 1,004,016, and 914,770 cases, for the age groups 18–59 years, 60–84 years, and 85+ years, respectively.
  • Epidemiology assessed for AKI showed that Germany accounted for the highest mortality-adjusted incident population of AKI in hospitalized patients in EU5, followed by the UK in 2020. The number of total mortality adjusted incidence of AKI in hospitalized patients is anticipated to be 906,731, 544,235, 506,725, 235,769 and 796,443 in 2020, for Germany, France, Italy, Spain, and UK, respectively.
  • Epidemiology assessed for AKI showed that Japan, in 2020, accounted for the second-highest mortality-adjusted incident population of AKI in hospitalized patients in 7MM, about 1,323,519 cases.

Country Wise- Acute Kidney Injury Epidemiology

The epidemiology segment also provides the Acute Kidney Injury epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Scope of the Report

  • The report covers the descriptive overview of Acute Kidney Injury, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Acute Kidney Injury.

Report Highlight

  • Ten Year Forecast of Acute Kidney Injury
  • 7MM Coverage
  • Delvelnsight has analysed incident population of Acute Kidney Injury in the 7MM which suggests that the patient pool will increase during the forecast period of 2021–2030.

Key Questions Answered

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Acute Kidney Injury?
  • What is the historical Acute Kidney Injury patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Acute Kidney Injury in the 7MM?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Kidney Injury?
  • Out of the above-mentioned countries, which country would have the highest incident population of Acute Kidney Injury during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Acute Kidney Injury report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Acute Kidney Injury market.
  • Quantify patient share distribution in the 7MM for Acute Kidney Injury.
  • The Acute Kidney Injury epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Acute Kidney Injury epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the Ten-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Acute Kidney Injury (AKI)

4. Disease Background and Overview

4.1. Introduction

4.2. Symptoms

4.3. Types of Acute Kidney Injury (AKI)

4.4. Stages Classification

4.5. Risk Factors

4.6. Etiology

4.7. Pathophysiology

4.8. Biomarkers

4.9. Diagnosis

4.9.1. RIFLE Criteria

4.9.2. AKIN Criteria

4.9.3. KDIGO criteria

4.10. NICE Guidelines on AKI: Prevention, Detection, and Management (2019)

4.10.1. Assessing Risk of AKI

4.10.2. Preventing AKI

4.10.3. Detecting AKI

4.10.4. Identifying the Cause of AKI

4.10.5. Information and Support for Patients and Carers

5. Epidemiology and Patient Population

5.1. Key Findings

5.1.1. Epidemiology Methodology

5.2. Total Incidence of Acute Kidney Injury (AKI) in Hospitalized Patients in the 7MM

5.3. Total Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM

5.4. Epidemiology of Acute Kidney Injury (AKI)

5.4.1. United States

5.4.2. Europe

5.4.3. Japan

5.5. The United States

5.5.1. Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients in the US

5.5.2. Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US

5.5.3. Stage-specific Incident Population of AKI in the United States

5.5.4. Age-specific Incident Population of AKI in the United States

5.6. EU5

5.6.1. Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients in EU5

5.6.2. Mortality Adjusted Incident Population of AKI in Hospitalized Patients in EU5

5.6.3. Stage-specific Incident Population of AKI in EU5

5.6.4. Age-specific Incident Population of AKI in EU5

5.7. Japan

5.7.1. Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients in Japan

5.7.2. Mortality Adjusted Incidence of AKI in Hospitalized Patients in Japan

5.7.3. Stage-specific Incident Population of AKI in Japan

5.7.4. Age-specific Incidence of AKI in Japan

6. Organizations contributing towards Acute Kidney Injury (AKI)

7. Patient Journey

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of Acute Kidney Injury (AKI) Market, and Epidemiology (2018–2030)

Table 2: Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification

Table 3: KDIGO Criteria

Table 4: Causes of AKI: Exposures and Susceptibilities for non-specific AKI

Table 5: Biomarkers of AKI

Table 6: RIFLE Criteria for ARF

Table 7: AKIN Criteria for ARF

Table 8: KDIGO Criteria for AKI

Table 9: Renal Replacement Therapy (RRT) Modalities for ARF

Table 10: Total Incident Population of AKI in Hospitalized Patients in the 7MM (2018–2030)

Table 11: Total Mortality Adjusted Incident Population of AKI in the 7MM (2018–2030)

Table 12: Total Incident Population of AKI in Hospitalized Patients in the US (2018–2030)

Table 13: Total Mortality Adjusted Incident Population of AKI in the US (2018–2030)

Table 14: Stage-specific Incident Population of AKI in the US (2018–2030)

Table 15: Age-specific Incident Population of AKI in the United States (2018–2030)

Table 16: Total Incidence of AKI in Hospitalized Patients in EU5 (2018–2030)

Table 17: Total Mortality Adjusted Incident Population of AKI in EU5 (2018–2030)

Table 18: Stage-specific Incident Population of AKI in EU5 (2018–2030)

Table 19: Age-specific Incident Population of AKI in EU5 (2018–2030)

Table 20: Total Incident Population of AKI in Hospitalized Patients in Japan (2018–2030)

Table 21: Mortality Adjusted Incident Population of AKI in Japan (2018–2030)

Table 22: Stage-specific Incident Population of AKI in Hospitalized Patients in Japan (2018–2030)

Table 23: Age-specific Incident Population of AKI in Japan (2018–2030)

Table 24: Organizations contributing toward Acute Kidney Injury (AKI)

List of Figures

Figure 1: Types of Acute Kidney Injury (AKI)

Figure 2: Risk factors associated with Acute Kidney Injury (AKI)

Figure 3: Common Causes of Acute Kidney Injury (AKI)

Figure 4: Pathophysiology of Acute Kidney Injury (AKI)

Figure 5: Biomarkers of Acute Kidney Injury (AKI)

Figure 6: Stage-based management of Acute Kidney Injury (AKI)

Figure 7: Total Incident Population of AKI in Hospitalized Patients in the 7MM (2018–2030)

Figure 8: Mortality Adjusted Incident Population of AKI in the 7MM (2018–2030)

Figure 9: Total Incident Population of AKI in Hospitalized Patients in the US (2018–2030)

Figure 10: Mortality Adjusted Incident Population of AKI in the US (2018–2030)

Figure 11: Stage-specific Incident Population of AKI in the US (2018–2030)

Figure 12: Age-specific Incident Population of AKI in the US (2018–2030)

Figure 13: Total Incident Population of AKI in Hospitalized Patients in EU5 (2018–2030)

Figure 14: Mortality Adjusted Incident Population of AKI in EU5 (2018–2030)

Figure 15: Stage-specific Incident Population of AKI in EU5 (2018–2030)

Figure 16: Age-specific Incident Population of AKI in EU5 (2018–2030)

Figure 17: Total Incident Population of AKI in Hospitalized Patients in Japan (2018–2030)

Figure 18: Mortality Adjusted Incident Population of AKI in Japan (2018–2030)

Figure 19: Stage-specific Incident Population of AKI in Japan (2018–2030)

Figure 20: Age-specific Incident Population of AKI in Japan (2018–2030)

Forward to Friend

Need A Quote